razoxane has been researched along with Angiogenesis, Pathologic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lacarrubba, F; Massimino, D; Micali, G; Musumeci, ML; Nasca, MR | 1 |
| Hellmann, K | 1 |
| Borgel, SD; Hollingshead, MG; Kaur, G; Kong, D; Melillo, G; Newton, DL; Rybak, SM; Sanovich, E; Sausville, EA | 1 |
| Anderson, H; Harris, AL; Miller, MP; Price, P; Propper, D; Wells, P; Yap, JT | 1 |
| Blann, A; Braybrooke, JP; Crew, J; Dobbs, N; Ganesan, TS; Han, C; Harris, AL; Mitchell, K; O'Byrne, KJ; Propper, DJ; Saunders, M; Smith, K; Stephens, R; Talbot, DC; Woodhull, J | 1 |
| Barleon, B; Dobbs, N; Hang, C; Harris, AL; Marme, D; Reusch, P | 1 |
2 review(s) available for razoxane and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Cutaneous vascular patterns in psoriasis.
Topics: Cell Proliferation; Cholecalciferol; Cyclosporine; Cytokines; Humans; Keratinocytes; Microvessels; Neovascularization, Pathologic; Psoriasis; Razoxane; Retinoids; Skin | 2010 |
Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Razoxane | 2003 |
3 trial(s) available for razoxane and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.
Topics: Antineoplastic Agents; Carbon Monoxide; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neovascularization, Pathologic; Oxygen Radioisotopes; Razoxane; Regional Blood Flow; Tomography, Emission-Computed; Water | 2003 |
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; E-Selectin; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Lymphokines; Male; Middle Aged; Neovascularization, Pathologic; Razoxane; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Time Factors; Topoisomerase II Inhibitors; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; von Willebrand Factor | 2000 |
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.
Topics: Antineoplastic Agents; Binding Sites; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Prognosis; Proto-Oncogene Proteins; Razoxane; Receptor Protein-Tyrosine Kinases; Receptor, TIE-2; Solubility; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2001 |
1 other study(ies) available for razoxane and Angiogenesis, Pathologic
| Article | Year |
|---|---|
"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Cell Hypoxia; Cyclohexanes; Drug Design; Endothelial Growth Factors; Endothelium, Vascular; Female; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Razoxane; Sesquiterpenes; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2003 |